X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Patent (667) 667
Journal Article (213) 213
Book Review (16) 16
Publication (9) 9
Book Chapter (5) 5
Book / eBook (3) 3
Magazine Article (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (629) 629
hygiene (629) 629
medical or veterinary science (629) 629
preparations for medical, dental, or toilet purposes (611) 611
specific therapeutic activity of chemical compounds ormedicinal preparations (513) 513
chemistry (410) 410
metallurgy (404) 404
organic chemistry (386) 386
heterocyclic compounds (284) 284
peptides (116) 116
index medicus (106) 106
humans (75) 75
artificial stone (53) 53
cements (53) 53
ceramics (53) 53
compositions thereof, e.g. mortars, concrete or like buildingmaterials (53) 53
concrete (53) 53
lime, magnesia (53) 53
refractories (53) 53
slag (53) 53
treatment of natural stone (53) 53
animals (52) 52
biochemistry (47) 47
investigating or analysing materials by determining theirchemical or physical properties (44) 44
measuring (44) 44
physics (44) 44
testing (44) 44
microbiology (43) 43
beer (42) 42
enzymology (42) 42
mutation or genetic engineering (42) 42
spirits (42) 42
vinegar (42) 42
wine (42) 42
oncology (35) 35
chemistry, medicinal (34) 34
biochemistry & molecular biology (32) 32
compositions or test papers therefor (32) 32
condition-responsive control in microbiological orenzymological processes (32) 32
measuring or testing processes involving enzymes, nucleicacids or microorganisms (32) 32
mice (32) 32
processes of preparing such compositions (32) 32
cell line, tumor (29) 29
chemistry, organic (26) 26
antineoplastic agents - pharmacology (25) 25
cancer (24) 24
female (24) 24
compositions thereof (22) 22
culture media (22) 22
microorganisms or enzymes (22) 22
propagating, preserving or maintaining microorganisms (22) 22
climate change mitigation technologies in the production orprocessing of goods (21) 21
general tagging of cross-sectional technologies spanning over several sections of the ipc (21) 21
general tagging of new technological developments (21) 21
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (21) 21
technologies or applications for mitigation or adaptation againstclimate change (21) 21
phosphatidylinositol 3-kinases - antagonists & inhibitors (20) 20
molecular sequence data (17) 17
amino acid sequence (16) 16
drug design (16) 16
models, molecular (16) 16
neoplasms - drug therapy (16) 16
protein kinase inhibitors - pharmacology (16) 16
signal transduction - drug effects (16) 16
structure-activity relationship (16) 16
xenograft model antitumor assays (16) 16
antitumor-activity (14) 14
cell biology (14) 14
cell proliferation - drug effects (14) 14
molecular structure (14) 14
research (14) 14
acyclic or carbocyclic compounds (13) 13
mice, nude (13) 13
pyrimidines - pharmacology (13) 13
apoptosis - drug effects (12) 12
drug discovery (12) 12
in-vivo (12) 12
phosphatidylinositol 3-kinases - metabolism (12) 12
protein binding (11) 11
signal transduction (11) 11
tumor cells, cultured (11) 11
adaptor proteins, signal transducing (10) 10
antineoplastic agents - chemistry (10) 10
antineoplastic agents - therapeutic use (10) 10
binding sites (10) 10
breast-cancer (10) 10
ligands (10) 10
protein kinase inhibitors - therapeutic use (10) 10
proto-oncogene proteins - metabolism (10) 10
proto-oncogene proteins c-akt - metabolism (10) 10
receptor, igf type 1 - antagonists & inhibitors (10) 10
specificity (10) 10
tor serine-threonine kinases (10) 10
tumor suppressor protein p53 - metabolism (10) 10
crystallography, x-ray (9) 9
dose-response relationship, drug (9) 9
grb2 adaptor protein (9) 9
imidazoles - pharmacology (9) 9
male (9) 9
mutation (9) 9
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (753) 753
French (188) 188
German (91) 91
Spanish (80) 80
Chinese (45) 45
Portuguese (45) 45
Korean (25) 25
Japanese (11) 11
Danish (8) 8
Arabic (6) 6
Slovenian (6) 6
Greek (5) 5
Croatian (4) 4
Icelandic (4) 4
Norwegian (4) 4
Polish (3) 3
Hungarian (2) 2
Italian (2) 2
Russian (2) 2
Czech (1) 1
Slovak (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Investigation, ISSN 0021-9738, 07/2010, Volume 120, Issue 7, pp. 2406 - 2413
Journal Article
Nature Medicine, ISSN 1078-8956, 12/2008, Volume 14, Issue 12, pp. 1351 - 1356
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 1/2009, Volume 106, Issue 1, pp. 268 - 273
Journal Article
Bioorganic and Medicinal Chemistry Letters, ISSN 0960-894X, 05/2013, Volume 23, Issue 9, pp. 2480 - 2485
A growing number of the elements identified in intracellular signaling events that affect cell growth and transformation are proteins that physically interact... 
hdm2 | Anticancer agent | Protein-protein interaction | hdmx | p53
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2019, Volume 62, Issue 5, pp. 2217 - 2217
Journal Article
Cancer Cell, ISSN 1535-6108, 2010, Volume 17, Issue 6, pp. 547 - 559
In mice, deletion and activation of results in lung tumors with a high penetrance of lymph node and distant metastases. We analyzed these primary and... 
CELLCYCLE | SIGNALING | EPITHELIAL-MESENCHYMAL TRANSITION | ONCOGENIC K-RAS | CANCER-CELLS | SUPPRESSOR | GENE | ONCOLOGY | SRC | KINASE INHIBITOR | EXPRESSION PROFILES | MUTATIONS | TUMORIGENESIS | Lung Neoplasms - drug therapy | Protein-Serine-Threonine Kinases - deficiency | Protein-Tyrosine Kinases - metabolism | Proto-Oncogene Proteins p21(ras) - genetics | Genomics | Humans | Lung Neoplasms - metabolism | Gene Expression Profiling | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Cell Movement - genetics | Phosphorylation - genetics | RNA Interference | Gene Expression Regulation, Neoplastic - genetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - metabolism | Signal Transduction - genetics | Enzyme Inhibitors - therapeutic use | Focal Adhesion Protein-Tyrosine Kinases - antagonists & inhibitors | Focal Adhesion Protein-Tyrosine Kinases - genetics | Focal Adhesions - genetics | Signal Transduction - drug effects | Mice, Nude | Cell Line, Tumor | Mice | TOR Serine-Threonine Kinases | src-Family Kinases - genetics | Protein-Tyrosine Kinases - antagonists & inhibitors | ras Proteins - genetics | Lung Neoplasms - pathology | Cell Transdifferentiation - genetics | Protein-Tyrosine Kinases - genetics | Neoplasm Metastasis - drug therapy | Mice, Mutant Strains | Protein-Serine-Threonine Kinases - antagonists & inhibitors | src-Family Kinases - metabolism | Female | Drug Therapy, Combination | Lung Neoplasms - genetics | Cell Adhesion - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Focal Adhesion Protein-Tyrosine Kinases - metabolism | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | src-Family Kinases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - genetics | Proto-Oncogene Proteins - genetics | Up-Regulation - genetics | Xenograft Model Antitumor Assays | Neoplasm Metastasis - genetics | Animals | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Focal Adhesions - metabolism | Proteomics | Protein Kinase Inhibitors - pharmacology | Oncology, Experimental | Analysis | Lung cancer | Development and progression | Metastasis | Research | Cancer | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2009, Volume 106, Issue 46, pp. 19503 - 19508
Non-small cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors... 
B lymphocytes | Cell death | Cell lines | Breast cancer | Down regulation | Genetic mutation | Apoptosis | Lung neoplasms | Cancer | Tumors | Mcl-1 | MEK | AKT | Acquired resistance | BIM | GEFITINIB | GROWTH-FACTOR-RECEPTOR | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | ANTITUMOR-ACTIVITY | PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET | acquired resistance | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | PATHWAY | T790M MUTATIONS | RAPAMYCIN INHIBITOR | Erlotinib Hydrochloride | Protein Kinases - metabolism | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Humans | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Quinolines - pharmacology | Female | MAP Kinase Kinase Kinases - antagonists & inhibitors | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Antineoplastic Combined Chemotherapy Protocols | Imidazoles - pharmacology | Breast Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - genetics | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Mice | TOR Serine-Threonine Kinases | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Physiological aspects | Research | Lung cancer, Non-small cell | Phosphotransferases | Health aspects | Mutation | Kinases | Lung cancer | Index Medicus | Biological Sciences
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2009, Volume 106, Issue 52, pp. 22299 - 22304
NVP-BEZ235 is a dual PI3K/mTOR inhibitor currently in phase I clinical trials. We profiled this compound against a panel of breast tumor cell lines to identify... 
Cell growth | Lethal dose 50 | Cell death | Cell lines | Medical genetics | Breast cancer | Genetic mutation | Tumors | Apoptosis | Cancer | mTOR | Small molecule | PI3K | Breat cancer | Kinase inhibitor | small molecule | COMPLEX | CASPASE-2 | MULTIDISCIPLINARY SCIENCES | DNA-DAMAGE | PTEN | PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET | VIVO ANTITUMOR-ACTIVITY | PI3K INHIBITOR | kinase inhibitor | breat cancer | MEK | GROWTH | RAPAMYCIN INHIBITOR | Caspase 9 - metabolism | Apoptosis - drug effects | Humans | Intracellular Signaling Peptides and Proteins - drug effects | Apoptosis - genetics | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Quinolines - pharmacology | Breast Neoplasms - metabolism | Genes, erbB-2 - drug effects | Female | PTEN Phosphohydrolase - genetics | Enzyme Inhibitors - pharmacology | Imidazoles - pharmacology | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Drug Resistance, Neoplasm - genetics | Poly(ADP-ribose) Polymerases - metabolism | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Gene Amplification | Signal Transduction - drug effects | Breast Neoplasms - pathology | Protein-Serine-Threonine Kinases - drug effects | Cell Line, Tumor | TOR Serine-Threonine Kinases | Apoptosis - physiology | Mutation | Drug Resistance, Neoplasm - physiology | Clinical trials | Inhibitor drugs | Index Medicus | Biological Sciences
Journal Article
Nature chemical biology, ISSN 1552-4450, 12/2014, Volume 10, Issue 12, pp. 1013 - 1019
Vps34 is a phosphoinositide 3-kinase (PI3K) class III isoform that has attracted major attention over the recent years because of its role in autophagy. Herein... 
KINASE VPS34 | LIPID KINASE | PHOSPHATIDYLINOSITOL 3-PHOSPHATE | T-CELL HOMEOSTASIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DISEASE | MECHANISMS | OPTIMIZATION | MAMMALIAN-CELLS | MTOR | REVEALS | Kidney - pathology | Antineoplastic Agents - chemical synthesis | Humans | Kidney - enzymology | Sirolimus - chemical synthesis | Autophagy - drug effects | Endosomes - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Lysosomes - metabolism | TOR Serine-Threonine Kinases - genetics | Adenosine Triphosphate - metabolism | Endosomes - drug effects | Class III Phosphatidylinositol 3-Kinases - chemistry | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Autophagy - genetics | Pyrimidinones - chemical synthesis | Everolimus | Lysosomes - drug effects | Protein Kinase Inhibitors - chemical synthesis | Catalytic Domain | Gene Expression | Sirolimus - analogs & derivatives | Signal Transduction | Pyridines - chemical synthesis | Recombinant Proteins - chemistry | Recombinant Proteins - genetics | Sirolimus - pharmacology | Drug Synergism | TOR Serine-Threonine Kinases - chemistry | Class III Phosphatidylinositol 3-Kinases - genetics | Cell Line, Tumor | Cell Proliferation - drug effects | Class III Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Molecular Docking Simulation | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Kinetics | Adenosine Triphosphate - chemistry | Proteins | Lipids | Kinases | Autophagy | Binding sites | Adenosine triphosphatase | Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2014, Volume 57, Issue 19, pp. 7888 - 7889
The field of antibody-drug conjugates (ADCs) has gained significant momentum after the recent regulatory approval of two ADCs, and significant research efforts... 
CHEMISTRY, MEDICINAL | Immunoconjugates - pharmacology | Animals | Drug Discovery | Antibodies, Monoclonal, Humanized - pharmacology | Humans | Trastuzumab | Index Medicus
Journal Article
Science Translational Medicine, ISSN 1946-6234, 09/2010, Volume 2, Issue 51, pp. 51ra70 - 51ra70
Journal Article
Cancer Research, ISSN 0008-5472, 08/2008, Volume 68, Issue 16, pp. 6598 - 6607
Journal Article
2012, RSC drug discovery series, ISBN 1849731748, Volume no. 19, xiii, 318
Kinase drug discovery remains an area of significant interest across academia and in the pharmaceutical industry. There are now around 13 FDA approved small... 
Drugs | Inhibitors | Research | Phosphotransferases | Drug Discovery | Protein kinases | antagonists & inhibitors | Clinical & internal medicine | Biochemistry | MEDICAL | Therapeutic use
Book